Company Introduction

cytena Bioprocess Solution co., Ltd (cBS) is founded in 2018 and is a subsidiary of a listed Sweden 3D printing company Cellink AB. cytena Bioprocess Solutions focuses on offering bioprocess solutions for, but not limited to, pharmaceuticals and top research institutes.

We have established collaboration with leading academic institutes and industrial companies in researching, development, and application. With the close connection with Cellink AB, we share the resources, experiences to bring our novel and comprehensive product into the global bioprocess market.

Cellimk is the world’s first universal bioink—an innovation 8 years in the making—which spurred our rapid rise to becoming the world’s leading bioprinting company. Fast-forward to 2021, after five successful acquisitions and several high-profile product launches, we are much more than a bioprinting company. We have embraced the emerging bio-convergence revolution, which is leveraging synergistic breakthroughs in the life sciences and technology to meet the world’s growing healthcare needs. By combining advances in biology, engineering, big data and AI, we are now the top bio-convergence company in the world, creating the future of medicine.

Brief description of main products or services 

C.BIRD™ is a high-throughput microbioreactor for parallel cultivations in 96-well plates, bringing production bioreactors environments into 150-1,600 µL microbioreactor scale.  It enables earlier identification of the highest producing and most stable clones, reduces later passaging steps and efforts of current scaling up process.C.BIRD™ can aslo screen and monitor valuable cell culture parameters for hundreds of cell lines from early stage, which helps scientists define the best clones sooner.